Reduces the likelihood of forgetting your weekly injection
As a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, it may surpass even tirzepatide for weight loss based on early clinical data
Rather than viewing glucagon as a metabolic enemy, researchers now recognize that balancing its effects alongside GLP-1 and GIP may unlock a new generation of diabetes and obesity treatments
Some patients notice a dark, gray, or missing area in their vision
Consistent quality remains an essential factor for laboratories pursuing reproducible outcomes and long-term research objectives
Biliary complications (cholelithiasis, cholecystitis) represent a class effect attributable to reduced gallbladder motility, with incidence approximately 1.5-2.5-fold higher than placebo in long-term trials